R
Rosemary Barrett
Researcher at Harvard University
Publications - 15
Citations - 1505
Rosemary Barrett is an academic researcher from Harvard University. The author has contributed to research in topics: Fms-Like Tyrosine Kinase 3 & Tyrosine kinase. The author has an hindex of 13, co-authored 14 publications receiving 1321 citations. Previous affiliations of Rosemary Barrett include Brigham and Women's Hospital & Novartis.
Papers
More filters
Journal ArticleDOI
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald,Antoine de Weck,Michael R. Schlabach,Eric Billy,Konstantinos J. Mavrakis,Gregory R. Hoffman,Dhiren Belur,Deborah Castelletti,Elizabeth Frias,Kalyani Gampa,Javad Golji,Iris Kao,Li Li,Philippe Megel,Thomas A. Perkins,Nadire Ramadan,David A. Ruddy,Serena J. Silver,Sosathya Sovath,Mark Stump,Odile Weber,Roland Widmer,Jianjun Yu,Kristine Yu,Yingzi Yue,Dorothee Abramowski,Elizabeth Ackley,Rosemary Barrett,Joel Berger,Julie L. Bernard,Rebecca Billig,Saskia M. Brachmann,Frank Buxton,Roger Caothien,Justina X. Caushi,Franklin Chung,Marta Cortes-Cros,Rosalie deBeaumont,Clara Delaunay,Aurore Desplat,William Duong,Donald A. Dwoske,Richard S. Eldridge,Ali Farsidjani,Fei Feng,JiaJia Feng,Daisy Flemming,William C. Forrester,Giorgio G. Galli,Zhenhai Gao,François Gauter,Veronica Gibaja,Kristy Haas,Marc Hattenberger,Tami Hood,Kristen Hurov,Zainab Jagani,Mathias Jenal,Jennifer Johnson,Michael D. Jones,Avnish Kapoor,Joshua M. Korn,Jilin Liu,Qiumei Liu,Shumei Liu,Yue Liu,Alice T. Loo,Kaitlin J. Macchi,Typhaine Martin,Gregory McAllister,A. B. Meyer,Sandra Mollé,Raymond Pagliarini,Tanushree Phadke,Brian Repko,Tanja Schouwey,Frances Shanahan,Qiong Shen,Christelle Stamm,Christine Stephan,Volker M. Stucke,Ralph Tiedt,Malini Varadarajan,Kavitha Venkatesan,Alberto C. Vitari,Marco Wallroth,Jan Weiler,Jing Zhang,Craig Mickanin,Vic E. Myer,Jeffery A. Porter,Albert Lai,Hans Bitter,Emma Lees,Nicholas Keen,Audrey Kauffmann,Frank Stegmeier,Francesco Hofmann,Tobias Schmelzle,William R. Sellers +99 more
TL;DR: A large-scale RNAi screen is conducted in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.
Journal ArticleDOI
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
Erik A. Nelson,Erik A. Nelson,Sarah R. Walker,Sarah R. Walker,Ellen Weisberg,Ellen Weisberg,Michal Bar-Natan,Michal Bar-Natan,Rosemary Barrett,Laurie B. Gashin,Shariya Terrell,Josephine L. Klitgaard,Josephine L. Klitgaard,Loredana Santo,Martha R. Addorio,Benjamin L. Ebert,Benjamin L. Ebert,James D. Griffin,James D. Griffin,David A. Frank,David A. Frank +20 more
TL;DR: Targeting STAT5 with pimozide and the kinase inhibitors imatinib or nilotinib shows enhanced effects in inhibiting STAT5 phosphorylation and in inducing apoptosis, suggesting that targeting STAT5 may be an effective strategy for the treatment of CML and other myeloproliferative diseases.
Journal ArticleDOI
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.
Ellen Weisberg,Rosemary Barrett,Qingsong Liu,Richard Stone,Richard Stone,Nathanael S. Gray,James D. Griffin +6 more
TL;DR: Mechanisms whereby AML cells develop resistance to FLT3 inhibitors, and the ways in which combination therapy could potentially be utilized to override drug resistance are discussed.
Journal ArticleDOI
Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Ellen Weisberg,Arghya Ray,Rosemary Barrett,Erik Nelson,Amanda L. Christie,Dale Porter,Christopher Sean Straub,Leigh Zawel,John F. Daley,Suzan Lazo-Kallanian,Richard Stone,Ilene Galinsky,David A. Frank,Andrew L. Kung,James D. Griffin +14 more
TL;DR: The results support the idea of using IAP inhibitors in conjunction with targeted tyrosine kinase inhibition to override drug resistance and suppress or eradicate residual disease.
Journal ArticleDOI
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations
Erik A. Nelson,Sarah R. Walker,Michael Xiang,Ellen Weisberg,Michal Bar-Natan,Rosemary Barrett,Suiyang Liu,Surender Kharbanda,Amanda L. Christie,Maria Nicolais,James D. Griffin,Richard Stone,Andrew L. Kung,David A. Frank +13 more
TL;DR: Pimozide reduces the tumor burden in a mouse model of FLT3-driven AML and may provide a new avenue for the treatment of AML, and these may be effective alone or in combination with tyrosine kinase inhibitors.